ArticleFrontiers in public health2026
Metabolic syndrome severity and all-cause mortality in the CLHLS biomarker subsample of older Chinese adults.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic syndrome (MetS) is a cluster of risk factors that increases cardiometabolic disease and mortality. A continuous MetS Score has been developed to quantify MetS severity, but its association with all-cause mortality in older Chinese adults remains unclear. Methods: We analyzed 2,443 participants from the Chinese Longitudinal Healthy Longevity Survey (CLHLS, 2008-2018 and 2011-2018). MetS Score was derived by confirmatory factor analysis using triglycerides, HDL-C, fasting glucose, systolic blood pressure, and BMI. Participants were categorized into quartiles (Q1-Q4). Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause mortality. Subgroup analyses examined heterogeneity by age, sex, residence, and other covariates, and restricted cubic splines explored dose-response relationships. Results: During 10,356 person-years of follow-up, 1,412 deaths occurred (136.3/1,000 person-years). Each 1-unit increase in MetS Score was associated with a 13.9% lower mortality risk (HR = 0.861, 95% CI: 0.787-0.942). The protective effect was concentrated in Q4 vs. Q1 (HR = 0.792, 95% CI: 0.669-0.938). Subgroup analyses showed stronger associations in those aged ≥80 years (HR = 0.785, 95% CI: 0.660-0.935), women (HR = 0.758, 95% CI: 0.617-0.931) and rural residents (HR = 0.817, 95% CI: 0.618-0.980). Restricted cubic splines confirmed a linear inverse association overall and among the ≥80 years group. Conclusion: MetS Score, reflecting MetS severity, was inversely associated with all-cause mortality in older Chinese adults, particularly among those aged ≥80 years. These findings suggest that higher MetS Score may paradoxically confer survival benefits in the older adults, warranting further mechanistic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.